Hologic's Mixed Financial Outlook: Neutral Rating Amid Growth Concerns and Margin Declines

Hologic's recent financial performance is mixed, with better-than-expected revenue and earnings per share for Q3 of FY2025, but slower organic sales growth and declining gross and operating margins. The company has increased its guidance for the full year but aims to achieve mid-single digit revenue growth in FY2026. Given these concerns, Needham analyst Michael Matson has maintained a Hold rating on HOLX stock.

Hologic (NASDAQ: HOLX), a leading medical technology company specializing in diagnostics and women’s health, reported its fiscal 2025 Q3 earnings on July 31, 2025. The company exceeded expectations with a revenue of $1.02 billion, up 1.2% year-over-year, and adjusted earnings per share (EPS) of $1.08, surpassing the high-end expectation of $1.07 [2].

The Diagnostics segment contributed $448.9 million, reflecting growth driven by molecular diagnostics sales. Breast Health generated $365.2 million, despite lower mammography equipment sales, supported by Endomagnetics and service contracts. The GYN Surgical division reported $178.4 million in revenue, bolstered by the Gynesonics acquisition and international sales. Skeletal Health revenue surged to $31.3 million, rounding out the company's robust performance [2].

However, organic sales growth was slower than expected, with non-GAAP gross margin slipping by 0.8 percentage points to 60.3%, and non-GAAP operating margin falling by 1.1 percentage points to 30.1%. The company attributed these declines to product mix changes, increased inventory reserves, and margin dilution from integrating recent acquisitions [1].

Despite these concerns, Hologic increased its full-year revenue guidance to $4.081 to $4.091 billion and expects non-GAAP EPS to range from $4.23 to $4.26. The company aims to achieve mid-single digit revenue growth in FY2026 [1].

Needham analyst Michael Matson has maintained a Hold rating on HOLX stock, citing the mixed Q3 performance and the impact of tariffs on inventory acquisition costs [1].

References:
[1] https://www.nasdaq.com/articles/hologic-holx-q3-revenue-beats-1
[2] https://www.ainvest.com/news/hologic-2025-q3-earnings-beats-expectations-net-income-grows-0-2-2508/